JP7439076B2 - 抗ｎｐｒ１抗体およびその使用 - Google Patents

抗ｎｐｒ１抗体およびその使用 Download PDF

Info

Publication number
JP7439076B2
JP7439076B2 JP2021522004A JP2021522004A JP7439076B2 JP 7439076 B2 JP7439076 B2 JP 7439076B2 JP 2021522004 A JP2021522004 A JP 2021522004A JP 2021522004 A JP2021522004 A JP 2021522004A JP 7439076 B2 JP7439076 B2 JP 7439076B2
Authority
JP
Japan
Prior art keywords
npr1
antibody
antigen
antibodies
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021522004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505604A5 (enExample
JP2022505604A (ja
Inventor
マイケル・ダン
ジア・スー
ジェイソン・マスタイティス
ジェスパー・グロマーダ
ローリ・モートン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2022505604A publication Critical patent/JP2022505604A/ja
Publication of JP2022505604A5 publication Critical patent/JP2022505604A5/ja
Priority to JP2024019151A priority Critical patent/JP7713051B2/ja
Application granted granted Critical
Publication of JP7439076B2 publication Critical patent/JP7439076B2/ja
Priority to JP2025116272A priority patent/JP2025148445A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021522004A 2018-10-23 2019-10-18 抗ｎｐｒ１抗体およびその使用 Active JP7439076B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024019151A JP7713051B2 (ja) 2018-10-23 2024-02-13 抗ｎｐｒ１抗体およびその使用
JP2025116272A JP2025148445A (ja) 2018-10-23 2025-07-10 抗ｎｐｒ１抗体およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862749557P 2018-10-23 2018-10-23
US62/749,557 2018-10-23
US201862755720P 2018-11-05 2018-11-05
US62/755,720 2018-11-05
PCT/US2019/057033 WO2020086406A2 (en) 2018-10-23 2019-10-18 Anti-npr1 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024019151A Division JP7713051B2 (ja) 2018-10-23 2024-02-13 抗ｎｐｒ１抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2022505604A JP2022505604A (ja) 2022-01-14
JP2022505604A5 JP2022505604A5 (enExample) 2022-10-24
JP7439076B2 true JP7439076B2 (ja) 2024-02-27

Family

ID=68732036

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021522004A Active JP7439076B2 (ja) 2018-10-23 2019-10-18 抗ｎｐｒ１抗体およびその使用
JP2024019151A Active JP7713051B2 (ja) 2018-10-23 2024-02-13 抗ｎｐｒ１抗体およびその使用
JP2025116272A Pending JP2025148445A (ja) 2018-10-23 2025-07-10 抗ｎｐｒ１抗体およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024019151A Active JP7713051B2 (ja) 2018-10-23 2024-02-13 抗ｎｐｒ１抗体およびその使用
JP2025116272A Pending JP2025148445A (ja) 2018-10-23 2025-07-10 抗ｎｐｒ１抗体およびその使用

Country Status (16)

Country Link
US (4) US11306148B2 (enExample)
EP (1) EP3870612A2 (enExample)
JP (3) JP7439076B2 (enExample)
KR (1) KR20210082207A (enExample)
CN (1) CN112805303B (enExample)
AU (1) AU2019368196B2 (enExample)
CA (1) CA3115102A1 (enExample)
CL (3) CL2021000942A1 (enExample)
CO (1) CO2021006663A2 (enExample)
IL (1) IL281297B2 (enExample)
MX (2) MX2021004284A (enExample)
MY (1) MY205168A (enExample)
PH (1) PH12021550255A1 (enExample)
SG (1) SG11202101037QA (enExample)
WO (1) WO2020086406A2 (enExample)
ZA (1) ZA202100714B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3115102A1 (en) 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Anti-npr1 antibodies and uses thereof
PH12021553101A1 (en) 2019-06-12 2023-10-02 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
EP4259661A1 (en) 2020-12-14 2023-10-18 Novartis AG Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
US12325752B2 (en) 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists
WO2023009529A2 (en) 2021-07-28 2023-02-02 Trustees Of Boston University Novel polypeptides and uses thereof
US20240327539A1 (en) 2021-10-11 2024-10-03 Regeneron Pharmaceuticals, Inc. Methods of effecting a hemodynamic change by administering an anti-npr1 antibody
WO2023107957A1 (en) 2021-12-06 2023-06-15 Regeneron Pharmaceuticals, Inc. Antagonist anti-npr1 antibodies and methods of use thereof
JP2025510997A (ja) 2022-03-30 2025-04-15 ノバルティス アーゲー 抗ナトリウム利尿ペプチド受容体１（ｎｐｒ１）抗体を使用して障害を治療する方法
AU2024287056A1 (en) * 2023-06-08 2025-12-11 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-npr1 antibody and pharmaceutical use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012510295A (ja) 2008-12-03 2012-05-10 ベーリンガー インゲルハイム ファーマスーティカルズ アイエヌシー． グアニル酸シクラーゼ受容体に対する抗体
JP2017099389A (ja) 2009-07-13 2017-06-08 ジェネンテック， インコーポレイテッド 癌治療のための診断方法および組成物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
US20100310561A1 (en) * 2007-06-06 2010-12-09 Boehringer Ingelheim International Gmbh Natriuretic fusion proteins
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
US10184942B2 (en) * 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
US9451770B2 (en) 2012-06-08 2016-09-27 Charles Despres Method of activating immune response in plants
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
WO2016131943A1 (en) * 2015-02-20 2016-08-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes
WO2017209553A2 (ko) 2016-06-03 2017-12-07 사회복지법인 삼성생명공익재단 환자 유래 세포를 이용한 항체 스크리닝 방법
WO2018075792A1 (en) * 2016-10-20 2018-04-26 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
US20190135804A1 (en) 2017-11-03 2019-05-09 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Compositions and methods for the inhibition of pruritus
CA3115102A1 (en) 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Anti-npr1 antibodies and uses thereof
US12703762B2 (en) 2018-12-18 2026-08-11 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
PH12021553101A1 (en) 2019-06-12 2023-10-02 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
EP4259661A1 (en) 2020-12-14 2023-10-18 Novartis AG Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
US12325752B2 (en) 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists
WO2023107957A1 (en) 2021-12-06 2023-06-15 Regeneron Pharmaceuticals, Inc. Antagonist anti-npr1 antibodies and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012510295A (ja) 2008-12-03 2012-05-10 ベーリンガー インゲルハイム ファーマスーティカルズ アイエヌシー． グアニル酸シクラーゼ受容体に対する抗体
JP2017099389A (ja) 2009-07-13 2017-06-08 ジェネンテック， インコーポレイテッド 癌治療のための診断方法および組成物

Also Published As

Publication number Publication date
CL2021000942A1 (es) 2022-02-04
AU2019368196B2 (en) 2026-04-16
KR20210082207A (ko) 2021-07-02
US11306148B2 (en) 2022-04-19
BR112021004329A2 (pt) 2021-08-03
US11820826B2 (en) 2023-11-21
CO2021006663A2 (es) 2021-06-10
CL2023001377A1 (es) 2023-10-20
CL2024000378A1 (es) 2024-08-23
JP2025148445A (ja) 2025-10-07
MX2024011444A (es) 2024-09-25
NZ773064A (en) 2024-04-26
CN112805303A (zh) 2021-05-14
MX2021004284A (es) 2021-05-31
US20240309103A1 (en) 2024-09-19
US20200123263A1 (en) 2020-04-23
ZA202100714B (en) 2023-07-26
US20240059780A1 (en) 2024-02-22
CN112805303B (zh) 2024-08-20
AU2019368196A1 (en) 2021-03-18
MY205168A (en) 2024-10-04
WO2020086406A2 (en) 2020-04-30
JP2024056834A (ja) 2024-04-23
SG11202101037QA (en) 2021-02-25
IL281297B1 (en) 2026-01-01
IL281297B2 (en) 2026-05-01
IL281297A (en) 2021-04-29
JP7713051B2 (ja) 2025-07-24
WO2020086406A3 (en) 2020-06-04
EP3870612A2 (en) 2021-09-01
PH12021550255A1 (en) 2021-11-03
US20220204634A1 (en) 2022-06-30
JP2022505604A (ja) 2022-01-14
CA3115102A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
JP7368543B2 (ja) 抗ｃ５抗体及びそれらの使用
JP7713051B2 (ja) 抗ｎｐｒ１抗体およびその使用
JP7759417B2 (ja) レプチン受容体を活性化させる抗原結合タンパク質
CA2773541A1 (en) High affinity human antibodies to human protease-activated receptor-2
IL303542A (en) Immunoglobulin proteins that bind to NPR1 agonists
KR20240112973A (ko) 길항제 항-npr1 항체 및 이의 사용 방법
EA046104B1 (ru) Анти-npr1 антитела и их применение
BR112021004329B1 (pt) Anticorpos anti-npr1 e composição farmacêutica
BR122024003574A2 (pt) Anticorpos anti-npr1, uso e método de produção dos mesmos, composição farmacêutica, moléculas polinucleotídicas isoladas, vetor, célula hospedeira, e combinação
EA053011B1 (ru) Иммуноглобулиновые белки, связывающиеся с агонистами npr1
EA048830B1 (ru) Полинуклеотиды, кодирующие антитела, которые связываются с лептиновым рецептором, и способ получения таких антител
EA041859B1 (ru) Антигенсвязывающие белки, которые активируют лептиновый рецептор
EA039858B1 (ru) Антитела против c5 и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230926

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240214

R150 Certificate of patent or registration of utility model

Ref document number: 7439076

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150